Shanghai Yizhong Pharmaceutical Co Ltd - Asset Resilience Ratio
Shanghai Yizhong Pharmaceutical Co Ltd (688091) has an Asset Resilience Ratio of 26.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Shanghai Yizhong Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Shanghai Yizhong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Yizhong Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Yizhong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai Yizhong Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥406.93 Million | 26.36% |
| Total Liquid Assets | CN¥406.93 Million | 26.36% |
Asset Resilience Insights
- Very High Liquidity: Shanghai Yizhong Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 26.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Yizhong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Yizhong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Shanghai Yizhong Pharmaceutical Co Ltd (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Yizhong Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.50% | CN¥21.70 Million ≈ $3.18 Million |
CN¥1.45 Billion ≈ $211.89 Million |
-19.18pp |
| 2023-12-31 | 20.68% | CN¥325.42 Million ≈ $47.62 Million |
CN¥1.57 Billion ≈ $230.23 Million |
-10.13pp |
| 2022-12-31 | 30.81% | CN¥417.36 Million ≈ $61.07 Million |
CN¥1.35 Billion ≈ $198.22 Million |
-39.38pp |
| 2021-12-31 | 70.19% | CN¥842.70 Million ≈ $123.31 Million |
CN¥1.20 Billion ≈ $175.68 Million |
+50.51pp |
| 2020-12-31 | 19.68% | CN¥50.94 Million ≈ $7.45 Million |
CN¥258.81 Million ≈ $37.87 Million |
-27.28pp |
| 2019-12-31 | 46.96% | CN¥130.38 Million ≈ $19.08 Million |
CN¥277.62 Million ≈ $40.62 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more